+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Non Invasive Prenatal Testing Market Size, Share & Trends Analysis Report by Gestation Period, Pregnancy Risk, Method, Technology, Product, Application, End-use, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 100 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 3989831
The global non invasive prenatal testing market size is expected to reach USD 8.16 billion by 2030., expanding at a CAGR of 10.06% from 2024 to 2030. Increasing incidence of chromosomal abnormalities is expected to accelerate market growth. Of all the countries, there is a substantial opportunity in China for non invasive prenatal screening, with nearly 14.65 million annual births and increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases. Various studies suggested that chromosomal abnormalities are found with a frequency of 1 in 166 newborns in the country, while trisomy 21 (Down syndrome) has a high incidence rate of 1 in 800 births, resulting in the birth of 32,000 newborns with Down syndrome every year. Families can benefit from accurate and early screening using NIPT to know about their baby's genetic issue. Thus, this high incidence rate is anticipated to boost the demand for prenatal tests.

With lockdowns due to COVID-19, NIPT gained attention because it delivers high accuracy screening with minimum risk of infection compared to invasive procedures like chorionic villus sampling and amniocentesis, both of which may necessitate hospitalization and put patients and medical professionals at risk of contracting COVID-19 infection. Moreover, there was increased demand for prescription of NIPTs; however, it was limited to a smaller number of eligible people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario pertaining to non invasive prenatal testing is highly variable. However, the support from the government and favorable insurance policies boost market growth. For instance, in the Netherlands, prenatal testing expenses are fully reimbursed in the second trimester, leading to increased adoption of these tests. Increase in government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China is anticipated to boost the demand for noninvasive prenatal testing solutions and services.

Key players in the market are focusing on new product development to strengthen their product portfolios and offer innovative products to customers. In March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetic laboratories. The probes on the cyto microarrays offer high-resolution detection of copy number variation and copy-neutral loss of heterozygosity related to neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.

Non Invasive Prenatal Testing Market Report Highlights

  • By gestation period, 13-24 weeks dominated the market in 2023 owing to the maximum number of non-invasive prenatal procedures carried out in the second trimester of the pregnancy
  • The low-risk pregnancy risk segment is expected to witness significant growth over the forecast period. Support from the government such as budget assignment for average-risk pregnancies contributed to the segment growth
  • Based on product, the cell-free DNA in maternal plasma tests segment accounted for the largest revenue share in 2023. Cell-free DNA is increasingly being utilized in predicting the risk of genetic disorders in prenatal care via various genetic analyses
  • Asia-Pacific is expected to exhibit the highest CAGR over the forecast period. Rising maternal age and improving healthcare infrastructure are likely to strengthen the market growth
  • North America dominated the market in 2023 due to high R&D investments, the presence of advanced healthcare facilities, and the development of whole genome sequencing

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Increasing average maternal age and rising incidence of chromosomal syndromes
3.4.2. High demand for early and noninvasive fetal testing procedure
3.4.3. Improvements in the reimbursement scenario
3.4.4. Rising collaborations and licensing agreements
3.5. Market Restraint Analysis
3.5.1. Ethical concerns with respect to reproductive genetics
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Gestation Period Business Analysis
4.1. Non-Invasive Prenatal Testing Market: Gestation Period Movement Analysis
4.2. 0-12 Weeks
4.2.1. 0-12 Weeks Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
4.3. 13-24 Weeks
4.3.1. 13-24 Weeks Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
4.4. 25-36 Weeks
4.4.1. 25-36 Weeks Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 5. Pregnancy Risk Business Analysis
5.1. Non-Invasive Prenatal Testing Market: Pregnancy Risk Movement Analysis
5.2. High & Average Risk
5.2.1. High & Average Risk Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
5.3. Low Risk
5.3.1. Low Risk Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 6. Method Risk Business Analysis
6.1. Non-Invasive Prenatal Testing Market: Method Movement Analysis
6.2. Ultrasound Detection
6.2.1. Ultrasound Detection Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
6.3. Biochemical Screening Tests
6.3.1. Biochemical Screening Tests Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
6.4. Cell-free DNA in Maternal Plasma Tests
6.4.1. Cell-free DNA in Maternal Plasma Tests Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 7. Technology Risk Business Analysis
7.1. Non-Invasive Prenatal Testing Market: Technology Movement Analysis
7.2. NGS
7.2.1. NGS Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
7.3. Array Technology
7.3.1. Array Technology Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
7.4. PCR
7.4.1. PCR Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
7.5. Others
7.5.1. Others Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 8. Product Risk Business Analysis
8.1. Non-Invasive Prenatal Testing Market: Product Movement Analysis
8.2. Consumables & Reagents
8.2.1. Consumables & Reagents Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
8.3. Instruments
8.3.1. Instruments Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 9. Application Risk Business Analysis
9.1. Non-Invasive Prenatal Testing Market: Application Movement Analysis
9.2. TRISOMY
9.2.1. TRISOMY Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
9.3. Microdeletion Syndrome
9.3.1. Microdeletion Syndrome Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
9.4. Others
9.4.1. Others Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Chapter 10. End-use Business Analysis
10.1. Non-Invasive Prenatal Testing Market: End-Use Movement Analysis
10.2. Hospitals & Clinics
10.2.1. Hospitals & Clinics Market, 2018-2030 (USD Million)
10.3. Diagnostics Laboratories
10.3.1. Diagnostics Laboratories Companies Market, 2018-2030 (USD Million)
10.4. Academic and Research Institutes
10.4.1. Academic and Research Institutes Market, 2018-2030 (USD Million)
Chapter 11. Regional Business Analysis
11.1. Non-Invasive Prenatal Testing Market Share By Region, 2023 & 2030
11.2. North America
11.2.1. North America Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.2.2. U.S.
11.2.2.1. Key Country Dynamics
11.2.2.2. Target Disease Prevalence
11.2.2.3. Competitive Scenario
11.2.2.4. Regulatory Framework
11.2.2.5. Reimbursement Scenario
11.2.2.6. U.S. Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.2.3. Canada
11.2.3.1. Key Country Dynamics
11.2.3.2. Target Disease Prevalence
11.2.3.3. Competitive Scenario
11.2.3.4. Regulatory Framework
11.2.3.5. Reimbursement Scenario
11.2.3.6. Canada Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3. Europe
11.3.1. Europe Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.2. Germany
11.3.2.1. Key Country Dynamics
11.3.2.2. Target Disease Prevalence
11.3.2.3. Competitive Scenario
11.3.2.4. Regulatory Framework
11.3.2.5. Reimbursement Scenario
11.3.2.6. Germany Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.3. UK
11.3.3.1. Key Country Dynamics
11.3.3.2. Target Disease Prevalence
11.3.3.3. Competitive Scenario
11.3.3.4. Regulatory Framework
11.3.3.5. Reimbursement Scenario
11.3.3.6. UK Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.4. France
11.3.4.1. Key Country Dynamics
11.3.4.2. Target Disease Prevalence
11.3.4.3. Competitive Scenario
11.3.4.4. Regulatory Framework
11.3.4.5. Reimbursement Scenario
11.3.4.6. France Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.5. Italy
11.3.5.1. Key Country Dynamics
11.3.5.2. Target Disease Prevalence
11.3.5.3. Competitive Scenario
11.3.5.4. Regulatory Framework
11.3.5.5. Reimbursement Scenario
11.3.5.6. Italy Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.6. Spain
11.3.6.1. Key Country Dynamics
11.3.6.2. Target Disease Prevalence
11.3.6.3. Competitive Scenario
11.3.6.4. Regulatory Framework
11.3.6.5. Reimbursement Scenario
11.3.6.6. Spain Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.7. Denmark
11.3.7.1. Key Country Dynamics
11.3.7.2. Target Disease Prevalence
11.3.7.3. Competitive Scenario
11.3.7.4. Regulatory Framework
11.3.7.5. Reimbursement Scenario
11.3.7.6. Denmark Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.8. Sweden
11.3.8.1. Key Country Dynamics
11.3.8.2. Target Disease Prevalence
11.3.8.3. Competitive Scenario
11.3.8.4. Regulatory Framework
11.3.8.5. Reimbursement Scenario
11.3.8.6. Sweden Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.3.9. Norway
11.3.9.1. Key Country Dynamics
11.3.9.2. Target Disease Prevalence
11.3.9.3. Competitive Scenario
11.3.9.4. Regulatory Framework
11.3.9.5. Reimbursement Scenario
11.3.9.6. Norway Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4. Asia-Pacific
11.4.1. Asia-Pacific Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.2. Japan
11.4.2.1. Key Country Dynamics
11.4.2.2. Target Disease Prevalence
11.4.2.3. Competitive Scenario
11.4.2.4. Regulatory Framework
11.4.2.5. Reimbursement Scenario
11.4.2.6. Japan Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.3. China
11.4.3.1. Key Country Dynamics
11.4.3.2. Target Disease Prevalence
11.4.3.3. Competitive Scenario
11.4.3.4. Regulatory Framework
11.4.3.5. Reimbursement Scenario
11.4.3.6. China Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.4. India
11.4.4.1. Key Country Dynamics
11.4.4.2. Target Disease Prevalence
11.4.4.3. Competitive Scenario
11.4.4.4. Regulatory Framework
11.4.4.5. Reimbursement Scenario
11.4.4.6. India Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.5. South Korea
11.4.5.1. Key Country Dynamics
11.4.5.2. Target Disease Prevalence
11.4.5.3. Competitive Scenario
11.4.5.4. Regulatory Framework
11.4.5.5. Reimbursement Scenario
11.4.5.6. South Korea Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.6. Australia
11.4.6.1. Key Country Dynamics
11.4.6.2. Target Disease Prevalence
11.4.6.3. Competitive Scenario
11.4.6.4. Regulatory Framework
11.4.6.5. Reimbursement Scenario
11.4.6.6. Australia Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.4.7. Thailand
11.4.7.1. Key Country Dynamics
11.4.7.2. Target Disease Prevalence
11.4.7.3. Competitive Scenario
11.4.7.4. Regulatory Framework
11.4.7.5. Reimbursement Scenario
11.4.7.6. Thailand Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.5. Latin America
11.5.1. Latin America Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.5.2. Brazil
11.5.2.1. Key Country Dynamics
11.5.2.2. Target Disease Prevalence
11.5.2.3. Competitive Scenario
11.5.2.4. Regulatory Framework
11.5.2.5. Reimbursement Scenario
11.5.2.6. Brazil Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.5.3. Mexico
11.5.3.1. Key Country Dynamics
11.5.3.2. Target Disease Prevalence
11.5.3.3. Competitive Scenario
11.5.3.4. Regulatory Framework
11.5.3.5. Reimbursement Scenario
11.5.3.6. Mexico Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.5.4. Argentina
11.5.4.1. Key Country Dynamics
11.5.4.2. Target Disease Prevalence
11.5.4.3. Competitive Scenario
11.5.4.4. Regulatory Framework
11.5.4.5. Reimbursement Scenario
11.5.4.6. Argentina Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.6. MEA
11.6.1. MEA Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.6.2. South Africa
11.6.2.1. Key Country Dynamics
11.6.2.2. Target Disease Prevalence
11.6.2.3. Competitive Scenario
11.6.2.4. Regulatory Framework
11.6.2.5. Reimbursement Scenario
11.6.2.6. South Africa Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.6.3. Saudi Arabia
11.6.3.1. Key Country Dynamics
11.6.3.2. Target Disease Prevalence
11.6.3.3. Competitive Scenario
11.6.3.4. Regulatory Framework
11.6.3.5. Reimbursement Scenario
11.6.3.6. Saudi Arabia Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.6.4. UAE
11.6.4.1. Key Country Dynamics
11.6.4.2. Target Disease Prevalence
11.6.4.3. Competitive Scenario
11.6.4.4. Regulatory Framework
11.6.4.5. Reimbursement Scenario
11.6.4.6. UAE Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
11.6.5. Kuwait
11.6.5.1. Key Country Dynamics
11.6.5.2. Target Disease Prevalence
11.6.5.3. Competitive Scenario
11.6.5.4. Regulatory Framework
11.6.5.5. Reimbursement Scenario
11.6.5.6. Kuwait Non-Invasive Prenatal Testing market, 2018-2030 (USD Million)
Chapter 12. Competitive Landscape
12.1. Participant’s overview
12.2. Financial performance
12.3. Participant categorization
12.3.1. Market Leaders
12.3.2. Non-Invasive Prenatal Testing market Share Analysis, 2023
12.3.3. Company Profiles
12.3.3.1. Genesis Genetics (CooperSurgical, Inc.)
12.3.3.1.1. Company Overview
12.3.3.1.2. Financial Performance
12.3.3.1.3. Product Benchmarking
12.3.3.1.4. Strategic Initiatives
12.3.3.2. Natera, Inc.
12.3.3.2.1. Company Overview
12.3.3.2.2. Financial Performance
12.3.3.2.3. Product Benchmarking
12.3.3.2.4. Strategic Initiatives
12.3.3.3. Centogene N.V.
12.3.3.3.1. Company Overview
12.3.3.3.2. Financial Performance
12.3.3.3.3. Product Benchmarking
12.3.3.3.4. Strategic Initiatives
12.3.3.4. Eurofins Scientific
12.3.3.4.1. Company Overview
12.3.3.4.2. Financial Performance
12.3.3.4.3. Product Benchmarking
12.3.3.4.4. Strategic Initiatives
12.3.3.5. MedGenome Labs Ltd.
12.3.3.5.1. Company Overview
12.3.3.5.2. Financial Performance
12.3.3.5.3. Product Benchmarking
12.3.3.5.4. Strategic Initiatives
12.3.3.6. F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
12.3.3.6.1. Company Overview
12.3.3.6.2. Financial Performance
12.3.3.6.3. Product Benchmarking
12.3.3.6.4. Strategic Initiatives
12.3.3.7. Myriad Women’s Health, Inc. (Counsyl, Inc.)
12.3.3.7.1. Company Overview
12.3.3.7.2. Financial Performance
12.3.3.7.3. Product Benchmarking
12.3.3.7.4. Strategic Initiatives
12.3.3.8. Progenity, Inc.
12.3.3.8.1. Company Overview
12.3.3.8.2. Financial Performance
12.3.3.8.3. Product Benchmarking
12.3.3.8.4. Strategic Initiatives
12.3.3.9. Qiagen
12.3.3.9.1. Company Overview
12.3.3.9.2. Financial Performance
12.3.3.9.3. Product Benchmarking
12.3.3.9.4. Strategic Initiatives
12.3.3.10. Laboratory Corp. of America Holdings
12.3.3.10.1. Company Overview
12.3.3.10.2. Financial Performance
12.3.3.10.3. Product Benchmarking
12.3.3.10.4. Strategic Initiatives
12.3.3.11. Illumina, Inc. (Verinata Health, Inc.)
12.3.3.11.1. Company Overview
12.3.3.11.2. Financial Performance
12.3.3.11.3. Product Benchmarking
12.3.3.11.4. Strategic Initiatives
12.3.3.12. Quest Diagnostics, Inc.
12.3.3.12.1. Company Overview
12.3.3.12.2. Financial Performance
12.3.3.12.3. Product Benchmarking
12.3.3.12.4. Strategic Initiatives
12.3.4. Strategy Mapping
12.3.4.1. Expansion
12.3.4.2. Acquisition
12.3.4.3. Collaborations
12.3.4.4. Product Type/Product Launch
12.3.4.5. Partnerships
12.3.4.6. Others
List of Tables
TABLE 1 List of secondary sources
TABLE 2 List of abbreviations
TABLE 3 Regulatory framework
TABLE 4 Risk of Trisomy 21 and chromosomal abnormalities with maternal age
TABLE 5 Average selling prices of non-invasive prenatal tests
TABLE 6 North America NIPT market estimates and forecasts, by country, 2018-2030 (USD Million)
TABLE 7 North America NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 8 North America NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 9 North America NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 10 North America NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 11 North America NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 12 North America NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 13 North America NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 14 U.S. NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 15 U.S. NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 16 U.S. NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 17 U.S. NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 18 U.S. NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 19 U.S. NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 20 U.S. NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 21 Canada NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 22 Canada NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 23 Canada NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 24 Canada NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 25 Canada NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 26 Canada NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 27 Canada NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 28 Europe NIPT market estimates and forecasts, by country, 2018-2030 (USD Million)
TABLE 29 Europe NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 30 Europe NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 31 Europe NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 32 Europe NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 33 Europe NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 34 Europe NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 35 Europe NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 36 U.K. NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 37 U.K. NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 38 U.K. NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 39 U.K. NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 40 U.K. NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 41 U.K. NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 42 U.K. NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 43 Germany NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 44 Germany NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 45 Germany NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 46 Germany NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 47 Germany NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 48 Germany NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 49 Germany NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 50 France NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 51 France NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 52 France NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 53 France NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 54 France NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 55 France NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 56 France NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 57 Italy NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 58 Italy NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 59 Italy NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 60 Italy NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 61 Italy NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 62 Italy NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 63 Italy NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 64 Spain NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 65 Spain NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 66 Spain NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 67 Spain NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 68 Spain NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 69 Spain NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 70 Spain NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 71 Denmark NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 72 Denmark NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 73 Denmark NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 74 Denmark NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 75 Denmark NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 76 Denmark NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 77 Denmark NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 78 Sweden NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 79 Sweden NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 80 Sweden NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 81 Sweden NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 82 Sweden NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 83 Sweden NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 84 Sweden NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 85 Norway NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 86 Norway NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 87 Norway NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 88 Norway NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 89 Norway NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 90 Norway NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 91 Norway NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 92 Asia-Pacific NIPT market estimates and forecasts, by country, 2018-2030 (USD Million)
TABLE 93 Asia-Pacific NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 94 Asia-Pacific NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 95 Asia-Pacific NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 96 Asia-Pacific NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 97 Asia-Pacific NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 98 Asia-Pacific NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 99 Asia-Pacific NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 100 Japan NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 101 Japan NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 102 Japan NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 103 Japan NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 104 Japan NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 105 Japan NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 106 Japan NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 107 China NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 108 China NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 109 China NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 110 China NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 111 China NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 112 China NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 113 China NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 114 India NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 115 India NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 116 India NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 117 India NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 118 India NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 119 India NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 120 India NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 121 South Korea NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 122 South Korea NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 123 South Korea NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 124 South Korea NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 125 South Korea NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 126 South Korea NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 127 South Korea NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 128 Australia NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 129 Australia NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 130 Australia NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 131 Australia NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 132 Australia NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 133 Australia NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 134 Australia NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 135 Thailand NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 136 Thailand NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 137 Thailand NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 138 Thailand NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 139 Thailand NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 140 Thailand NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 141 Thailand NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 142 Latin America NIPT market estimates and forecasts, by country, 2018-2030 (USD Million)
TABLE 143 Latin America NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 144 Latin America NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 145 Latin America NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 146 Latin America NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 147 Latin America NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 148 Latin America NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 149 Latin America NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 150 Brazil NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 151 Brazil NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 152 Brazil NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 153 Brazil NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 154 Brazil NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 155 Brazil NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 156 Brazil NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 157 Mexico NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 158 Mexico NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 159 Mexico NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 160 Mexico NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 161 Mexico NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 162 Mexico NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 163 Mexico NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 164 Argentina NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 165 Argentina NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 166 Argentina NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 167 Argentina NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 168 Argentina NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 169 Argentina NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 170 Argentina NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 171 MEA NIPT market estimates and forecasts, by country, 2018-2030 (USD Million)
TABLE 172 MEA NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 173 MEA NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 174 MEA NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 175 MEA NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 176 MEA NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 177 MEA NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 178 MEA NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 179 South Africa NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 180 South Africa NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 181 South Africa NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 182 South Africa NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 183 South Africa NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 184 South Africa NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 185 South Africa NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 186 Saudi Arabia NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 187 Saudi Arabia NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 188 Saudi Arabia NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 189 Saudi Arabia NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 190 Saudi Arabia NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 191 Saudi Arabia NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 192 Saudi Arabia NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 193 UAE NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 194 UAE NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 195 UAE NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 196 UAE NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 197 UAE NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 198 UAE NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 199 UAE NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
TABLE 200 Kuwait NIPT market estimates and forecasts, by gestation period, 2018-2030 (USD Million)
TABLE 201 Kuwait NIPT market estimates and forecasts, by pregnancy risk, 2018-2030 (USD Million)
TABLE 202 Kuwait NIPT market estimates and forecasts, by method, 2018-2030 (USD Million)
TABLE 203 Kuwait NIPT market estimates and forecasts, by technology, 2018-2030 (USD Million)
TABLE 204 Kuwait NIPT market estimates and forecasts, by product, 2018-2030 (USD Million)
TABLE 205 Kuwait NIPT market estimates and forecasts, by application, 2018-2030 (USD Million)
TABLE 206 Kuwait NIPT market estimates and forecasts, by end-use, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information Procurement
Figure 3 Primary Research Pattern
Figure 4 Market Research Approaches
Figure 5 Value Chain-Based Sizing & Forecasting
Figure 6 Market Formulation & Validation
Figure 7 Non-Invasive Prenatal Testing Market Segmentation
Figure 8 Market Snapshot, 2023
Figure 9 Market Trends & Outlook
Figure 10 Market Driver Relevance Analysis (Current & Future Impact)
Figure 11 Market Restraint Relevance Analysis (Current & Future Impact)
Figure 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
Figure 13 Porter’s Five Forces Analysis
Figure 14 Global Non-Invasive Prenatal Testing Market: Gestation Period Movement Analysis
Figure 15 Global Non-Invasive Prenatal Testing Market, by 0-12 Weeks, 2018-2030 (USD Million)
Figure 16 Global Non-Invasive Prenatal Testing Market, by 13-24 Weeks, 2018-2030 (USD Million)
Figure 17 Global Non-Invasive Prenatal Testing Market: Pregnancy Risk Movement Analysis
Figure 18 Global Non-Invasive Prenatal Testing Market, by High & Average Risk, 2018-2030 (USD Million)
Figure 19 Global Non-Invasive Prenatal Testing Market, by Low Risk, 2018-2030 (USD Million)
Figure 20 Global Non-Invasive Prenatal Testing Market: Method Movement Analysis
Figure 21 Global Non-Invasive Prenatal Testing Market, by Ultrasound Detection, 2018-2030 (USD Million)
Figure 22 Global Non-Invasive Prenatal Testing Market, by Biochemical Screening Tests, 2018-2030 (USD Million)
Figure 23 Global Non-Invasive Prenatal Testing Market, by Cell-free DNA in Maternal Plasma Tests, 2018-2030 (USD Million)
Figure 24 Global Non-Invasive Prenatal Testing Market: Technology Movement Analysis
Figure 25 Global Non-Invasive Prenatal Testing Market, by NGS, 2018-2030 (USD Million)
Figure 26 Global Non-Invasive Prenatal Testing Market, by Array Technology, 2018-2030 (USD Million)
Figure 27 Global Non-Invasive Prenatal Testing Market, by PCR, 2018-2030 (USD Million)
Figure 28 Global Non-Invasive Prenatal Testing Market, by Others, 2018-2030 (USD Million)
Figure 29 Global Non-Invasive Prenatal Testing Market: Product Movement Analysis
Figure 30 Global Non-Invasive Prenatal Testing Market, by Consumables & Reagents, 2018-2030 (USD Million)
Figure 31 Global Non-Invasive Prenatal Testing Market, by Instruments, 2018-2030 (USD Million)
Figure 32 Global Non-Invasive Prenatal Testing Market: Application Movement Analysis
Figure 33 Global Non-Invasive Prenatal Testing Market, by Trisomy, 2018-2030 (USD Million)
Figure 34 Global Non-Invasive Prenatal Testing Market, by Microdeletion Syndrome, 2018-2030 (USD Million)
Figure 35 Global Non-Invasive Prenatal Testing Market, by Other Applications, 2018-2030 (USD Million)
Figure 36 Global Non-Invasive Prenatal Testing Market: End-use Movement Analysis
Figure 37 Global Non-Invasive Prenatal Testing Market, by Hospitals & Clinics, 2018-2030 (USD Million)
Figure 38 Global Non-Invasive Prenatal Testing Market, by Diagnostic Laboratories, 2018-2030 (USD Million)
Figure 39 Regional Marketplace: Key Takeaways
Figure 40 Regional Outlook, 2023 & 2030
Figure 41 Global Non-Invasive Prenatal Testing Market: Region Movement Analysis
Figure 42 North America Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 43 U.S. Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 44 Canada Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 45 Europe Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 46 Germany Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 47 UK Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 48 France Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 49 Italy Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 50 Spain Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 51 Denmark Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 52 Sweden Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 53 Norway Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 54 Asia-Pacific Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 55 Japan Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 56 China Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 57 India Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 58 Australia Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 59 South Korea Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 60 Thailand Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 61 Latin America Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 62 Brazil Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 63 Mexico Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 64 Argentina Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 65 Middle East and Africa Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 66 South Africa Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 67 Saudi Arabia Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 68 UAE Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)
Figure 69 Kuwait Non-Invasive Prenatal Testing Market, 2018-2030 (USD Million)

Companies Mentioned

  • Genesis Genetics (CooperSurgical, Inc.)
  • Natera, Inc.
  • Centogene N.V.
  • Eurofins Scientific
  • MedGenome Labs Ltd.
  • F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
  • Myriad Women’s Health, Inc. (Counsyl, Inc.)
  • Progenity, Inc.
  • Qiagen
  • Laboratory Corp. of America Holdings
  • Illumina, Inc. (Verinata Health, Inc.)
  • Quest Diagnostics, Inc.

Methodology

Loading
LOADING...

Table Information